Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Quercis Pharma AG currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner, CRAIGO, BAHAR ALAWI, and is situated within a distinct art unit. CRAIGO, BAHAR ALAWI is the busiest examiner for the portfolio, holding 1 pending office action.
The presence of a distinct art unit for the pending action reflects a focused prosecution effort within the pharmaceutical field. With only 1 pending office action in the entire portfolio, the company's current interactions with the patent office are limited to a single examiner. This means that CRAIGO, BAHAR ALAWI is responsible for the entirety of the company's current pending biotechnology matters. This centralized structure ensures that the company's primary technical focus is being reviewed by a dedicated specialist in a specific examination group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18611871 | METHOD FOR TREATING ZIKA VIRUS INFECTION WITH QUERCETIN-CONTAINING COMPOSITIONS | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18611871 | METHOD FOR TREATING ZIKA VIRUS INFECTION WITH QUERCETIN-CONTAINING COMPOSITIONS | CRAIGO, BAHAR ALAWI | 1699 | §103DP | Non-Final OA | — | Pending | Mar 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial